InvestorsObserver
×
News Home

Decibel Therapeutics Inc (DBTX) Stock: What Does the Chart Say Thursday?

Thursday, July 21, 2022 03:51 PM | InvestorsObserver Analysts

Mentioned in this article

Decibel Therapeutics Inc (DBTX) Stock: What Does the Chart Say Thursday?

The market has been high on Decibel Therapeutics Inc (DBTX) stock recently. DBTX gets a Bullish score from InvestorsObserver Stock Sentiment Indicator.

Sentiment Score - ,bullish
Decibel Therapeutics Inc has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on DBTX!

What is Stock Sentiment?

In investing, sentiment generally means whether or not a given security is in favor with investors. It is typically a pretty short-term metric that relies entirely on technical analysis. That means it doesn’t incorporate anything to do with the health or profitability of the underlying company. Sentiment is how investors, or the market, feels about a stock. There are lots of ways to measure sentiment. At the core, sentiment is pretty easy to understand. If a stock is going up, investors must be bullish, while if it is going down, sentiment is bearish. InvestorsObserver’s Sentiment Indicator looks at price trends over the past week and also considers changes in volume. Increasing volume can mean a trend is getting stronger, while decreasing volume can mean a trend is nearing a conclusion. For stocks that have options, our system also considers the balance between calls, which are often bets that the price will go up, and puts, which are frequently bets that the price will fall.

What's Happening With DBTX Stock Today?

Decibel Therapeutics Inc (DBTX) stock is trading at $5.54 as of 3:43 PM on Thursday, Jul 21, a rise of $0.49, or 9.7% from the previous closing price of $5.05. The stock has traded between $4.93 and $5.59 so far today. Volume today is light. So far 107,479 shares have traded compared to average volume of 473,191 shares.

More About Decibel Therapeutics Inc

Decibel Therapeutics Inc is a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments for hearing and balance disorders. It aims to restore and improve hearing and balance through the restoration and regeneration of functional hair cells and non-sensory support cells within the inner ear. Its lead gene therapy product candidate is DB-OTO which provides hearing to individuals born with profound hearing loss due to an OTOF deficiency. The firm's pipeline products comprise DB-ATO, AAV.103, AAV.104, AAV.201, DB-020, and Cochlear Hair Cell Regeneration. Click Here to get the full Stock Report for Decibel Therapeutics Inc stock.

You May Also Like

Get the InvestorsObserver App

InvestorsObserver App
iOS App Android App